全文获取类型
收费全文 | 7497篇 |
免费 | 289篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 111篇 |
妇产科学 | 51篇 |
基础医学 | 408篇 |
口腔科学 | 34篇 |
临床医学 | 505篇 |
内科学 | 1969篇 |
皮肤病学 | 15篇 |
神经病学 | 126篇 |
特种医学 | 314篇 |
外科学 | 3514篇 |
综合类 | 65篇 |
预防医学 | 85篇 |
眼科学 | 21篇 |
药学 | 95篇 |
1篇 | |
中国医学 | 7篇 |
肿瘤学 | 473篇 |
出版年
2024年 | 2篇 |
2023年 | 606篇 |
2022年 | 696篇 |
2021年 | 874篇 |
2020年 | 721篇 |
2019年 | 343篇 |
2018年 | 349篇 |
2017年 | 259篇 |
2016年 | 278篇 |
2015年 | 297篇 |
2014年 | 708篇 |
2013年 | 572篇 |
2012年 | 259篇 |
2011年 | 96篇 |
2010年 | 349篇 |
2009年 | 325篇 |
2008年 | 91篇 |
2007年 | 115篇 |
2006年 | 121篇 |
2005年 | 59篇 |
2004年 | 53篇 |
2003年 | 39篇 |
2002年 | 71篇 |
2001年 | 52篇 |
2000年 | 49篇 |
1999年 | 79篇 |
1998年 | 89篇 |
1997年 | 25篇 |
1996年 | 47篇 |
1995年 | 32篇 |
1994年 | 34篇 |
1993年 | 16篇 |
1992年 | 9篇 |
1991年 | 8篇 |
1990年 | 9篇 |
1989年 | 10篇 |
1988年 | 13篇 |
1987年 | 4篇 |
1985年 | 3篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1978年 | 7篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1973年 | 1篇 |
1972年 | 3篇 |
1970年 | 3篇 |
排序方式: 共有7811条查询结果,搜索用时 375 毫秒
42.
43.
《Vaccine》2016,34(24):2663-2670
Human metapneumovirus (HMPV) is a major cause of morbidity and mortality from acute lower respiratory tract illness, with most individuals seropositive by age five. Despite the presence of neutralizing antibodies, secondary infections are common and can be severe in young, elderly, and immunocompromised persons. Preclinical vaccine studies for HMPV have suggested a need for a balanced antibody and T cell immune response to enhance protection and avoid lung immunopathology. We infected transgenic mice expressing human HLA-A*0201 with HMPV and used ELISPOT to screen overlapping and predicted epitope peptides. We identified six novel HLA-A2 restricted CD8+ T cell (TCD8) epitopes, with M39–47 (M39) immunodominant. Tetramer staining detected M39-specific TCD8 in lungs and spleen of HMPV-immune mice. Immunization with adjuvant-formulated M39 peptide reduced lung virus titers upon challenge. Finally, we show that TCD8 from HLA-A*0201 positive humans recognize M39 by IFNγ ELISPOT and tetramer staining. These results will facilitate HMPV vaccine development and human studies. 相似文献
44.
45.
《Journal of pharmaceutical sciences》2019,108(10):3425-3433
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. 相似文献
46.
47.
48.
49.
50.